Literature DB >> 15147033

Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses.

Raymond W Lam1, Sidney H Kennedy.   

Abstract

The goal of therapy in the management of patients with major depressive disorder is to achieve and sustain remission. Extensive data on strategies to achieve remission have been published, and more recently, many of these data have been subject to systematic review and metaanalyses. This review compares data from metaanalyses and more recent trials on some of the therapies that may help to achieve remission. Strategies that have demonstrated improved rates of full remission in the treatment of depression include venlafaxine as initial antidepressant therapy, which has been shown to provide higher rates of remission when compared with serotonin reuptake inhibitors and tricyclic antidepressants. For patients who do not respond to initial medication treatment, treatments such as psychotherapy, exercise, light therapy, alternative medicines, and counselling have demonstrated benefits over placebo and may enhance remission rates when used in combination with antidepressants. Preventing relapse and sustaining the fully remitted state over the long term is also important in the management of depression. Continuing antidepressant therapy has been associated with excellent long-term outcomes for many patients. Randomized controlled clinical trials conducted in the last 5 years provide very good evidence to show that achieving and sustaining the fully remitted state is an attainable goal in the management of patients with depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147033

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  7 in total

1.  Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Authors:  Wen-Jiun Chou; Shin-Jaw Chen; Ying-Sheue Chen; Hsin-Yi Liang; Chih-Chien Lin; Ching-Shu Tang; Yu-Shu Huang; Chin-Bin Yeh; Miao-Chun Chou; Dai-Yueh Lin; Po-Hsun Hou; Yu-Yu Wu; Hung-Jen Liu; Ya-Fen Huang; Kai-Ling Hwang; Chin-Hong Chan; Chia-Ho Pan; Hsueh-Ling Chang; Chi-Fen Huang; Ju-Wei Hsu
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

2.  STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!

Authors:  Raymond W Lam; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2015-01       Impact factor: 4.356

3.  What drives referral from primary care physicians to mental health specialists? A randomized trial using actors portraying depressive symptoms.

Authors:  Richard L Kravitz; Peter Franks; Mitchell Feldman; Lisa S Meredith; Ladson Hinton; Carol Franz; Paul Duberstein; Ronald M Epstein
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

4.  Genome-wide association studies of placebo and duloxetine response in major depressive disorder.

Authors:  M Maciukiewicz; V S Marshe; A K Tiwari; T M Fonseka; N Freeman; J L Kennedy; S Rotzinger; J A Foster; S H Kennedy; D J Müller
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

5.  The forced swim test as a model of depressive-like behavior.

Authors:  Roni Yankelevitch-Yahav; Motty Franko; Avrham Huly; Ravid Doron
Journal:  J Vis Exp       Date:  2015-03-02       Impact factor: 1.355

Review 6.  Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.

Authors:  Danielle Hen-Shoval; Aron Weller; Abraham Weizman; Gal Shoval
Journal:  Int J Environ Res Public Health       Date:  2022-01-04       Impact factor: 3.390

7.  Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome.

Authors:  David Shapiro; Ian A Cook; Dmitry M Davydov; Cristina Ottaviani; Andrew F Leuchter; Michelle Abrams
Journal:  Evid Based Complement Alternat Med       Date:  2007-12       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.